Collazo-Saldaña P, Hernández-Muñoz M, Silva-Gaona ÓG, Rangel-Aguilera JM, Sánchez-Navarro M

Language: Spanish
References: 15
Page: 101-105
PDF size: 155.35 Kb.

ABSTRACT

Bacterial meningitis is a major cause of morbidity and mortality in children under five years of age. Streptococcus pneumoniae is the main causative agent; its epidemiology has changed following the introduction of conjugate vaccines (pcv10 and pcv13). Serotype replacement has occurred, with new ones emerging, such as serotype 35b.
We present the case of a one-year-old male infant, previously healthy and fully up-to-date with the national vaccination schedule. The illness began with fever and irritability, and within a few days, refractory seizures developed. During hospitalization, he developed pancytopenia and upper gastrointestinal bleeding. Despite supportive care, he died on the sixth day after the onset of symptoms. Postmortem cerebrospinal fluid analysis confirmed bacterial meningitis caused by Streptococcus pneumoniae serotype 35b. This highlights the clinical and epidemiological relevance of emerging serotypes not included in the national vaccination schedule.

REFERENCES

1. Villalpando-Carrión, S., Henao-Martínez, A.I. y Franco-Paredes, C., “Epidemiology and clinical outcomes ofbacterial meningitis in children and adults in low- andmiddle-income countries”, Curr Trop Med Rep, 2024, 11(2): 60-67.

2. Bautista-Márquez, A., Richardson, V., Ortiz-Orozco, O.,Luna-Cruz, M.E., Carnalla-Barajas, M.N., Echaniz-Avilés,G. et al., “Prevalence of pneumococcal disease, serotypedistribution, and antimicrobial susceptibility inMexican children younger than 5 years of age”, ArchMed Res, 2013, 44 (2): 142-150.

3. Soto-Noguerón, A., Carnalla-Barajas, M.N., Solórzano-Santos, F., Arredondo-García, J.L., Arzate-Barbosa,P., Tinoco-Favila, J.C. et al., “Streptococcus pneumoniaeas cause of infection in infants less than 60 days of age:serotypes and antimicrobial susceptibility”, Int J InfectDis, 2016, 42: 69-73.

4. Torres-Martínez, C., Camacho-Moreno, G., Patiño-Niño,J., Coronell, W., Leal, A.L. y Gámez, G., “Pneumococcaldiseases in Colombia: epidemiological analysis beforeand during the universal children immunization againstStreptococcus pneumoniae in the light of a vaccinechange in 2022”, Infectio, 2024, 28 (1): 33-44.

5. Savulescu, C., Krizova, P., Valentiner-Branth, P., Ladhani,S., Rinta-Kokko, H., Levy, C. et al., “Effectiveness of10- and 13-valent pneumococcal conjugate vaccinesagainst invasive pneumococcal disease in Europeanchildren: SpIDnet observational multicentre study”,Vaccine, 2022, 40 (29): 3963-3974.

6. Rodríguez-Muñoz, L., Solórzano-Santos, F., Flores-Reyes, E.A., Escalante-López, J., Rodríguez-Balderas,D.E., Echániz-Avilés, G. et al., “Invasive infections bynon-vaccine serotypes of Streptococcus pneumoniae:a growing threat”, Bol Med Hosp Infant Mex, 2019, 76(6): 281-286.

7. Olarte, L., Kaplan, S.L., Barson, W.J., Romero, J.R., Lin,P.L., Tan, T.Q. et al., “Emergence of multidrug-resistantpneumococcal serotype 35b among children in the UnitedStates”, J Clin Microbiol, 2017, 55 (3): 724-734.

8. Miyazaki, H., Chang, B., Ogawa, M., Shibuya, R., Takata,M., Nakamura, S. et al., “Bacteriological characteristicsand changes of Streptococcus pneumoniae serotype35b after vaccine implementation in Japan”, EpidemiolInfect, 2024, 152: e114.

9. World Health Organization (who), “Defeating meningitisby 2030: a global road map”, Ginebra, WHO, 2021.Disponible en: https://www.who.int/publications/i/item/9789240026407.

10. Angoulvant, F., Cohen, R., Doit, C., Elbez, A., Werner,A., Béchet, S. et al., “Trends in antibiotic resistance ofStreptococcus pneumoniae and Haemophilus influenzaeisolated from nasopharyngeal flora in children withacute otitis media in France before and after 13-valentpneumococcal conjugate vaccine introduction”, bmcInfect Dis, 2015, 15: 236.

11. Soto-Noguerón, A., Carnalla-Barajas, M.N., Sánchez-González, G., Solórzano-Santos, F., Macías-Parra,M., Díaz-Jiménez, V. et al., “Distribution of pneumococcalserotypes causing invasive and non-invasive diseasesin children in Mexico after introduction of pcv13(2012-2023): results from the givebpvac group”, Vaccine,2025, 55: 127031.

12. Clinical and Laboratory Standards Institute (clsi), “Performancestandards for antimicrobial susceptibility testing”, 34ª ed., clsi supplement M100, Wayne, PA,clsi, 2024.

13. Yamada, N., Nakamoto, T., Takei, H., Shoji, T., Takahashi,K., Sato, J. et al., “Two cases of bacterial meningitis dueto meropenem-resistant Streptococcus pneumoniae: Athreat of serotype 35b, st 558 lineage”, J Infect Chemother,2020, 26 (7): 745-748.

14. Tomioka, M., Nakamura, K., Duan, S., Matsumoto, K.,Shindo, T., Hoshi, K. et al., “Bacteremia and meningitiscaused by penicillin-resistant Streptococcus pneumoniaeserotype 35b successfully treated with ceftriaxonecombined with vancomycin followed by linezolid”, InternMed, 2025, 64 (11): 1761-1766.

15. Kobayashi, M., Leidner, A.J., Gierke, R., Farrar, J.L., Morgan,R.L., Campos-Outcalt, D. et al., “Use of 21-valentpneumococcal conjugate vaccine among U.S. adults:recommendations of the Advisory Committee on ImmunizationPractices – United States, 2024”, mmwr MorbMortal Wkly Rep, 2024, 73 (36): 793-798.